The Novo Nordisk Foundation has awarded a grant of 1,860,959 euros to support the development of new influenza virus blockers
The activity of influenza A viruses is inhibited by biomimetic multivalent receptor interactions. Image Credit: Freie Universität Berlin The Novo Nordisk Foundation has awarded an international research team led by Professor Rainer Haag 1,860,959 euros to support the development of precision glycol-oligomers as hetero-multivalent pandemic influenza virus blockers.
The influenza A virus (IAV) anchors to host cell surfaces with different surface proteins to initiate the infection cycle. These surface proteins are responsible for virus adhesion to host cells and the release of newly produced viruses. ...
TO READ THIS ARTICLE, CREATE YOUR ACCOUNT
And extend your reading, free of charge and with no commitment.
